The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Reverse Merger | IPO

Total Raised


About Millendo Therapeutics

Millendo Therapeutics, previously known as Atterocor, is a drug development company focused on a treatment for adrenal cancer. The company seeks to develop adrenal-targeting therapy for the treatment of adrenocortical carcinoma (ACC) patients.

Millendo Therapeutics Headquarter Location

301 North Main Street Suite 100

Ann Arbor, Michigan, 48104,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Millendo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Millendo Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Millendo Therapeutics Patents

Millendo Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Piperazines, Piperidines, National supreme courts, Synthetic opioids, Adrenal gland disorders


Application Date


Grant Date



Related Topics

Piperazines, Piperidines, National supreme courts, Synthetic opioids, Adrenal gland disorders



Latest Millendo Therapeutics News

Casper Sleep : Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?

Jul 15, 2021

07/15/2021 | 09:32am EDT Message : *Required fields NEW YORK, July 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment. View original content to download multimedia: SOURCE InvestorsObserver

Millendo Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Millendo Therapeutics Rank

  • When was Millendo Therapeutics founded?

    Millendo Therapeutics was founded in 2012.

  • Where is Millendo Therapeutics's headquarters?

    Millendo Therapeutics's headquarters is located at 301 North Main Street, Ann Arbor.

  • What is Millendo Therapeutics's latest funding round?

    Millendo Therapeutics's latest funding round is Reverse Merger.

  • How much did Millendo Therapeutics raise?

    Millendo Therapeutics raised a total of $128.29M.

  • Who are the investors of Millendo Therapeutics?

    Investors of Millendo Therapeutics include OvaScience, Frazier Healthcare Partners, New Enterprise Associates, Roche Venture Fund, 5AM Ventures and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.